0001683168-22-003173.txt : 20220504 0001683168-22-003173.hdr.sgml : 20220504 20220504152917 ACCESSION NUMBER: 0001683168-22-003173 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220504 DATE AS OF CHANGE: 20220504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUONCOLOGY LABS INC CENTRAL INDEX KEY: 0001066719 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 650019376 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26113 FILM NUMBER: 22891246 BUSINESS ADDRESS: STREET 1: PO BOX 26496 CITY: SCOTTSDALE STATE: AZ ZIP: 85255 BUSINESS PHONE: 602-793-8058 MAIL ADDRESS: STREET 1: PO BOX 26496 CITY: SCOTTSDALE STATE: AZ ZIP: 85255 10-Q 1 nuoncology_i10q-033122.htm FORM 10-Q
0001066719 false 2022 Q1 --12-31 0001066719 2022-01-01 2022-03-31 0001066719 2022-03-31 0001066719 2021-12-31 0001066719 2021-01-01 2021-03-31 0001066719 NONE:PreferredStockSeriesAMember 2020-12-31 0001066719 us-gaap:CommonStockMember 2020-12-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001066719 us-gaap:RetainedEarningsMember 2020-12-31 0001066719 2020-12-31 0001066719 NONE:PreferredStockSeriesAMember 2021-12-31 0001066719 us-gaap:CommonStockMember 2021-12-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001066719 us-gaap:RetainedEarningsMember 2021-12-31 0001066719 NONE:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001066719 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001066719 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001066719 NONE:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001066719 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001066719 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001066719 NONE:PreferredStockSeriesAMember 2021-03-31 0001066719 us-gaap:CommonStockMember 2021-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001066719 us-gaap:RetainedEarningsMember 2021-03-31 0001066719 2021-03-31 0001066719 NONE:PreferredStockSeriesAMember 2022-03-31 0001066719 us-gaap:CommonStockMember 2022-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001066719 us-gaap:RetainedEarningsMember 2022-03-31 0001066719 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001066719 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001066719 NONE:RhondaKeaveneyMember 2022-01-01 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the quarterly period ended March 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________.

  

Commission file number: 000-26113

 

NUONCOLOGY LABS, INC.

(Exact name of registrant as specified in its charter)

 

Florida   65-0019376

(State of other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

7339 E. Williams Drive

Unit 26496

Scottsdale, AZ 85255

(Address of Principal Executive Offices) (Zip Code)

 

602.793.8058

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☒   No ☐ 

 

As of March 31, 2022, there were 98,783,664 shares outstanding of the registrant’s Common Stock.

 

As of March 31, 2022, there were 500,000 shares outstanding of the registrant’s Convertible Series A Preferred Stock.

 

 

   

 

 

Item 1. Financial Statements.

 

NUONCOLOGY LABS, INC.

 

FINANCIAL STATEMENTS

 

 

Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021 (Audited) 3
   
Statements of Operations for the Three Months ended March 31, 2022 and 2021 (Unaudited) 4
   
Statements of Changes in Stockholders’ Deficit for the Three Months ended March 31, 2022 and 2021 (Unaudited) 5
   
Statements of Cash Flows for the Three Months ended March 31, 2022 and 2021 (Unaudited) 6
   
Notes to Financial Statements (Unaudited) 7

 

 

 

 

 2 

 

 

 

NUONCOLOGY LABS, INC.

BALANCE SHEETS

 

   March 31,   December 31, 
   2022   2021 
ASSETS  (Unaudited)   (Audited) 
Current Assets:          
           
Cash  $   $ 
           
Total Assets  $   $ 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
Current Liabilities:          
Loan payable – related party  $12,281   $ 
Total Liabilities   12,281     
           
Stockholders' Deficit:          
Series A Preferred stock, $0.001 par value; 10,000,000,000 shares authorized, 500,000 and shares issued and outstanding   500    500 
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 98,783,664 shares issued and outstanding   9,878    9,878 
Additional paid-in capital   10,837,376    10,837,376 
Accumulated deficit   (10,860,035)   (10,847,754)
Total Stockholders’ Deficit   (12,281)    
           
Total Liabilities and Stockholders' Deficit  $   $ 

    

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 

 3 

 

 

NUONCOLOGY LABS, INC.

STATEMENTS OF OPERATIONS

(Unaudited)

 

           
   For the Three Months Ended 
   March 31, 
   2022   2021 
Operating Expenses:          
General & administrative expenses  $12,281   $ 
Total operating expenses   12,281     
           
Loss from operations   (12,281)    
           
Loss before income taxes   (12,281)    
           
Provision for income taxes        
           
Net loss  $(12,281)  $ 
           
Basic and diluted loss per share  $(0.00)  $ 
           
Basic and diluted weighted average shares   98,783,664    98,283,664 

 

 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 4 

 

 

 

NUONCOLOGY LABS, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

THREE MONTHS ENDED MARCH 31, 2021 AND 2022

(Unaudited)

 

 

                                    
   Series A
Preferred Stock
   Common Stock   Additional
Paid in
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance at December 31, 2020      $    98,283,664   $9,828   $10,808,707   $(10,818,535)  $ 
Net loss                            
Balance at March 31, 2021      $    98,283,664   $9,828   $10,808,707   $(10,818,535)  $ 

 

    

   Series A Preferred Stock   Common Stock   Additional
Paid in
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance at December 31, 2021   500,000   $500    98,783,664   $9,878   $10,837,376   $(10,847,754)  $ 
Net loss                       (12,281)   (12,281)
Balance at March 31, 2022   500,000   $500    98,783,664   $9,878   $10,837,376   $(10,860,035)  $(12,281)

 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 

 5 

 

 

 

NUONCOLOGY LABS, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

           
   For the Three Months Ended 
   March 31, 
   2022   2021 
Cash flows from operating activities:          
           
Net loss  $(12,281)  $ 
Adjustments to reconcile net loss to net cash used in operating activities:          
Changes in assets and liabilities:          
           
Net cash used in operating activities   (12,281)    
           
Cash flows from investing activities:        
           
Cash flows from financing activities:          
Cash advance - related party   12,281     
Net cash provided by financing activities   12,281     
           
Net change in cash        
           
Cash, beginning of year        
           
Cash, end of year  $   $ 

 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

 6 

 

 

NUONCOLOGY LABS, INC.

Notes to the Unaudited Financial Statements

March 31, 2022

 

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

NuOncology Labs, Inc. (the “Company”) was incorporated under the laws of the State of Florida on November 6, 1994 as Choice Book & Video, Inc. The company had no business operations at this time. On April 9, 1998, the Company filed an amendment to its Articles of Incorporation and changed its name to Littman Resources, Inc. with a mergers and acquisitions business model.

 

In June 1998 the Company merged with NuOncology Labs, Inc. whereby NuOncology Labs, Inc. became the surviving company and on June 26, 1998, filed an amendment to its Articles of Incorporation and changed its name to NuOnclology Labs, Inc.

 

NuOncology Labs, Inc. operated as commercial laboratory and provided predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues and other oncological laboratory testing services and products. NLAB’s operations included development, identification, testing and licensing of cancer treatment compounds.

 

Business operations for NuOncology Labs, Inc. were abandoned by former management and a custodianship action, as described in the subsequent paragraph, was commenced in 2021.

 

On October 1, 2021, the Circuit Court of the Nineth Judicial Circuit in and for Orange County, Florida granted the Application for Appointment of Custodian as a result of the absence of a functioning board of directors and the revocation of the Company’s charter. The order appointed Small Cap Compliance, LLC (the “Custodian”) custodian with the right to appoint officers and directors, negotiate and compromise debt, execute contracts, issue stock, and authorize new classes of stock.

 

The court awarded custodianship to the Custodian based on the absence of a functioning board of directors, revocation of the company’s charter, and abandonment of the business. At this time, the Custodian appointed Rhonda Keaveney as sole officer and director.

 

The Custodian attempted to contact the Company’s officers and directors through letters, emails, and phone calls, with no success.

 

Small Cap Compliance, LLC (“SCC”) is a shareholder in the Company and applied to the Court for an Order appointing SCC as the Custodian. This application was for the purpose of reinstating NLAB’s corporate charter to do business and restoring value to the Company for the benefit of the stockholders.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

The Company’s unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the three month period ending March 31, 2022 and not necessarily indicative of the results to be expected for the full year ending December 31, 2022. These unaudited financial statements should be read in conjunction with the financial statements and related notes for the year ended December 31, 2021.

 

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 

 

 

 

 7 

 

 

Cash and cash equivalents

We consider all highly liquid securities with original maturities of three months or less when acquired to be cash equivalents. There were no cash equivalents as of March 31, 2022 and December 31, 2021.

 

Recent Accounting Pronouncements

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

NOTE 3 - GOING CONCERN

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has no revenue and has an accumulated a deficit as of March 31, 2022. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

 

NOTE 4 – COMMON STOCK

 

On October 10, 2021, the Company amended its Article of Incorporation, increasing its authorized common stock from 100,000,000 to 1,000,000,000 (1 billion), par value $0.0001.

 

NOTE 5 – PREFERRED STOCK

 

On October 10, 2021, the Company amended its Article of Incorporation, creating and designating 10,000,000 shares of Series A preferred stock, par value $0.001.

 

Each share of Convertible Series A Preferred Stock is convertible into 1,000 shares of common stock. In addition, the Convertible Series A Preferred Stock has voting privileges of 1,000 votes for each share held.

 

Our sole officer and director holds 100% of the Convertible Series A Preferred Stock.

 

NOTE 6 – RELATED PARTY TRANSACTIONS

 

During the three months ended March 31, 2022, Rhonda Keaveney, CEO, advanced the Company $12,281 to pay for general operating expenses, The advance in non-interest bearing and due on demand.

 

NOTE 7– SUBSEQUENT EVENTS

 

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has determined that it does not have any material subsequent events to disclose in these unaudited financial statements.

 

 

 

 

 

 8 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following management’s discussion and analysis (“MD&A”) should be read in conjunction with financial statements of NuOncology Labs, Inc. for the three and nine months ended March 31, 20221 and 2021, and the notes thereto.

 

Safe Harbor for Forward-Looking Statements

 

Certain statements included in this MD&A constitute forward-looking statements, including those identified by the expressions anticipate, believe, plan, estimate, expect, intend, and similar expressions to the extent they relate to NuOncology Labs, Inc. or its management. These forward-looking statements are not facts, promises, or guarantees; rather, they reflect current expectations regarding future results or events. These forward-looking statements are subject to risks and uncertainties that could cause actual results, activities, performance, or events to differ materially from current expectations. These include risks related to revenue growth, operating results, industry, products, and litigation, as well as the matters discussed in NuOncology Labs, Inc.’s MD&A. Readers should not place undue reliance on any such forward-looking statements. NuOncology Labs, Inc. disclaims any obligation to publicly update or to revise any such statements to reflect any change in the Company’s expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

NuOncology Labs, Inc. is a blank check company and has no operations. Our business plan includes acquisitions of operating companies. In summary, NLAB is focused on raising capital for its business plan. As of this filing, we have not raised any capital and our business is not yet operational.

 

Results of Operations

 

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes included in this report

 

Three Months Ended March 31, 2022 and 2021 

 

Revenue

 

For the three and three months ended March 31, 2022 and 2021, the Company had not generated any revenues.

 

Operating Expenses

 

Operating expenses for the three months ended March 31, 2022 were $12,281 compared to $0 for the three months ended Marhc 31, 2021.

  

Operating expenses increased in 2022 due to other professional fee and other general and administrative fees incurred for this period.

 

For the three months ended March 31, 2022, professional fees were $12,281, an increase of $12,281, as compared to $0 for the three months ended of March 31, 2021. 

 

The increase is related to accounting and audit fees, and SEC filing fees between the two periods.

 

Other Income and Expenses

 

For the three and three months ended March 31, 2022 and 2022, the Company did not have any other income or expenses.

 

 

 

 9 

 

 

Net Income (Loss)

 

For the three-month ended March 31, 2022, the Company had a net loss of $12,281 compared to the three-month period ended March 31, 2021 of a net loss of $0.

 

For the three months ended March 31, 2022, the Company had a net loss of $12,281 compared to a net loss of $0 for the year ended December 31, 2022.

 

The net loss resulted from increase of operating expenses

 

Liquidity and Capital Resources

 

As of March 31, 2022, we had no cash and a working capital deficit of $12,281.

 

Operating Activities

 

For three months ended March 31 ,2022 net operating loss increased $12,281 as compared to $0 for the three months ended March 31, 2021. Accounts payable and accrued expenses increased by $12,281 at compared to $0 for the three months ended March 31, 2021. The increase in accrued expenses is related to other professional fees.

 

Investing Activities

  

No investing activities occurred during the three months ended March 31, 2022 and 2021.

 

Financing Activities

 

During the three months ended March 31, 2022, the Company received advances of $12,281 from a related party for working capital purposes. During the three months ended March 31, 2022 the Company issued $0 common stock for cash.

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements with any party.

 

Critical Accounting Policies

 

Our discussion and analysis of results of operations and financial condition are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to provisions for uncollectible accounts receivable, inventories, valuation of intangible assets and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

The accounting policies that we follow are set forth in Note 2 to our financial statements as included in the SEC report filed. These accounting policies conform to accounting principles generally accepted in the United States and have been consistently applied in the preparation of the financial statements.

  

 

 

 

 10 

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

As a “smaller reporting company,” as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information in this Item.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. The framework used by management in making that assessment was the criteria set forth in the document entitled “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based upon that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure for the reason described below.

 

Because of our limited operations, we have limited number of employees which prohibits a segregation of duties. In addition, we lack a formal audit committee with a financial expert. As we grow and expand our operations, we will engage additional employees and experts as needed. However, there can be no assurance that our operations will expand.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 

 

 

 

 

 

 

 

 11 

 

 

PART II OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not a party to any material or legal proceeding, and, to our knowledge, none is contemplated or threatened.

 

Item 1A. Risk Factors

 

We are a smaller reporting company and, as a result, are not required to provide the information under this item. Please review the risk factors identified in Item 1.A of our 2021 Form 10.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the three months ended March 31, 2022, the Company did not sell any unregistered securities.

 

Item 3. Defaults Upon Senior Securities

 

There have been no defaults upon senior securities.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

As a “smaller reporting company,” as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information in this Item.

 

Item 6. Exhibits

 

Exhibit No.   Description
     
31.1   Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2   Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350*
32.2   Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350*
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)*
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document*
101.SCH   Inline XBRL Taxonomy Extension Schema Document*
104   Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).

_______________________

  * Filed Herewith.

 

 

 

 

 

 12 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 Date: May 4, 2022 NUONCOLOGY LABS, INC.
   
   
  By:       /s/ Rhonda Keaveney
  Name       Rhonda Keaveney
  Title        Chief Executive Officer

 

 

 

 

 13 

 

EX-31.1 2 nuoncology_ex3101.htm CERTIFICATION

Exhibit 31.1

 

SECTION 302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Rhonda Keaveney, certify that:

 

1. I have reviewed this annual report on Form 10-Q of NuOncology Labs, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:   May 4, 2022   By:   /s/ Rhonda Keaveney  
       

Rhonda Keaveney

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

EX-31.2 3 nuoncology_ex3102.htm CERTIFICATION

Exhibit 31.2

 

SECTION 302 CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Rhonda Keaveney, certify that:

 

1. I have reviewed this annual report on Form 10-Q of NuOncology Labs, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:   May 4, 2022   By:   /s/ Rhonda Keaveney  
       

Rhonda Keaveney

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

 

EX-32.1 4 nuoncology_ex3201.htm CERTIFICATION

Exhibit 32.1

 

SECTION 906 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of NuOncology Labs, Inc. (the “Company”) for the period ended March 31, 2022 as filed with the SEC (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date:   May 4, 2022   By:   /s/ Rhonda Keaveney  
       

Rhonda Keaveney

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

EX-32.2 5 nuoncology_ex3202.htm CERTIFICATION

Exhibit 32.2

 

SECTION 906 CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of NuOncology Labs, Inc. (the “Company”) for the period ended March 31, 2022 as filed with the SEC (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date:   May 4, 2022   By:   /s/ Rhonda Keaveney  
       

Rhonda Keaveney

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

 

 

EX-101.SCH 6 none-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PREFERRED STOCK link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - PREFERRED STOCK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 none-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 none-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 none-20220331_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock Series A [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Related Party [Axis] Rhonda Keaveney [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets: Cash Total Assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Loan payable – related party Total Liabilities Stockholders' Deficit: Series A Preferred stock, $0.001 par value; 10,000,000,000 shares authorized, 500,000 and shares issued and outstanding Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 98,783,664 shares issued and outstanding Additional paid-in capital Accumulated deficit Total Stockholders’ Deficit Total Liabilities and Stockholders' Deficit Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Operating Expenses: General & administrative expenses Total operating expenses Loss from operations Loss before income taxes Provision for income taxes Net loss Basic and diluted loss per share Basic and diluted weighted average shares Statement [Table] Statement [Line Items] Beginning balance, value Shares, Outstanding, Beginning Balance Ending balance, value Shares, Outstanding, Ending Balance Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Changes in assets and liabilities: Net cash used in operating activities Cash flows from investing activities: Cash flows from financing activities: Cash advance - related party Net cash provided by financing activities Net change in cash Cash, beginning of year Cash, end of year Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES GOING CONCERN Equity [Abstract] COMMON STOCK PREFERRED STOCK Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates Cash and cash equivalents Recent Accounting Pronouncements Cash Equivalents, at Carrying Value Revenues Schedule of Stock by Class [Table] Class of Stock [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Proceeds from Related Party Debt Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Shares, Outstanding Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents EX-101.PRE 10 none-20220331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
3 Months Ended
Mar. 31, 2022
shares
Cover [Abstract]  
Document Type 10-Q
Amendment Flag false
Document Quarterly Report true
Document Transition Report false
Document Period End Date Mar. 31, 2022
Document Fiscal Period Focus Q1
Document Fiscal Year Focus 2022
Current Fiscal Year End Date --12-31
Entity File Number 000-26113
Entity Registrant Name NUONCOLOGY LABS, INC.
Entity Central Index Key 0001066719
Entity Tax Identification Number 65-0019376
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 7339 E. Williams Drive
Entity Address, Address Line Two Unit 26496
Entity Address, City or Town Scottsdale
Entity Address, State or Province AZ
Entity Address, Postal Zip Code 85255
City Area Code 602
Local Phone Number 793.8058
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Non-accelerated Filer
Entity Small Business true
Entity Emerging Growth Company false
Entity Shell Company true
Entity Common Stock, Shares Outstanding 98,783,664
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 0 $ 0
Total Assets 0 0
Current Liabilities:    
Loan payable – related party 12,281 0
Total Liabilities 12,281 0
Stockholders' Deficit:    
Series A Preferred stock, $0.001 par value; 10,000,000,000 shares authorized, 500,000 and shares issued and outstanding 500 500
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 98,783,664 shares issued and outstanding 9,878 9,878
Additional paid-in capital 10,837,376 10,837,376
Accumulated deficit (10,860,035) (10,847,754)
Total Stockholders’ Deficit (12,281) 0
Total Liabilities and Stockholders' Deficit $ 0 $ 0
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 10,000,000,000 10,000,000,000
Preferred Stock, Shares Issued 500,000 500,000
Preferred Stock, Shares Outstanding 500,000 500,000
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 1,000,000,000 1,000,000,000
Common Stock, Shares, Issued 98,783,664 98,783,664
Common Stock, Shares, Outstanding 98,783,664 98,783,664
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Expenses:    
General & administrative expenses $ 12,281 $ 0
Total operating expenses 12,281 0
Loss from operations (12,281) 0
Loss before income taxes (12,281) 0
Provision for income taxes 0 0
Net loss $ (12,281) $ 0
Basic and diluted loss per share $ (0.00)
Basic and diluted weighted average shares 98,783,664 98,283,664
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Preferred Stock Series A [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 0 $ 9,828 $ 10,808,707 $ (10,818,535) $ 0
Shares, Outstanding, Beginning Balance at Dec. 31, 2020 0 98,283,664      
Net loss $ 0 $ 0 0 0 0
Ending balance, value at Mar. 31, 2021 $ 0 $ 9,828 10,808,707 (10,818,535) 0
Shares, Outstanding, Ending Balance at Mar. 31, 2021 0 98,283,664      
Beginning balance, value at Dec. 31, 2021 $ 500 $ 9,878 10,837,376 (10,847,754) 0
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 500,000 98,783,664      
Net loss $ 0 $ 0 0 (12,281) (12,281)
Ending balance, value at Mar. 31, 2022 $ 500 $ 9,878 $ 10,837,376 $ (10,860,035) $ (12,281)
Shares, Outstanding, Ending Balance at Mar. 31, 2022 500,000 98,783,664      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (12,281) $ 0
Changes in assets and liabilities:    
Net cash used in operating activities (12,281) 0
Cash flows from investing activities: 0 0
Cash flows from financing activities:    
Cash advance - related party 12,281 0
Net cash provided by financing activities 12,281 0
Net change in cash 0 0
Cash, beginning of year 0 0
Cash, end of year $ 0 $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANIZATION AND DESCRIPTION OF BUSINESS
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

NuOncology Labs, Inc. (the “Company”) was incorporated under the laws of the State of Florida on November 6, 1994 as Choice Book & Video, Inc. The company had no business operations at this time. On April 9, 1998, the Company filed an amendment to its Articles of Incorporation and changed its name to Littman Resources, Inc. with a mergers and acquisitions business model.

 

In June 1998 the Company merged with NuOncology Labs, Inc. whereby NuOncology Labs, Inc. became the surviving company and on June 26, 1998, filed an amendment to its Articles of Incorporation and changed its name to NuOnclology Labs, Inc.

 

NuOncology Labs, Inc. operated as commercial laboratory and provided predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues and other oncological laboratory testing services and products. NLAB’s operations included development, identification, testing and licensing of cancer treatment compounds.

 

Business operations for NuOncology Labs, Inc. were abandoned by former management and a custodianship action, as described in the subsequent paragraph, was commenced in 2021.

 

On October 1, 2021, the Circuit Court of the Nineth Judicial Circuit in and for Orange County, Florida granted the Application for Appointment of Custodian as a result of the absence of a functioning board of directors and the revocation of the Company’s charter. The order appointed Small Cap Compliance, LLC (the “Custodian”) custodian with the right to appoint officers and directors, negotiate and compromise debt, execute contracts, issue stock, and authorize new classes of stock.

 

The court awarded custodianship to the Custodian based on the absence of a functioning board of directors, revocation of the company’s charter, and abandonment of the business. At this time, the Custodian appointed Rhonda Keaveney as sole officer and director.

 

The Custodian attempted to contact the Company’s officers and directors through letters, emails, and phone calls, with no success.

 

Small Cap Compliance, LLC (“SCC”) is a shareholder in the Company and applied to the Court for an Order appointing SCC as the Custodian. This application was for the purpose of reinstating NLAB’s corporate charter to do business and restoring value to the Company for the benefit of the stockholders.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

The Company’s unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the three month period ending March 31, 2022 and not necessarily indicative of the results to be expected for the full year ending December 31, 2022. These unaudited financial statements should be read in conjunction with the financial statements and related notes for the year ended December 31, 2021.

 

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

We consider all highly liquid securities with original maturities of three months or less when acquired to be cash equivalents. There were no cash equivalents as of March 31, 2022 and December 31, 2021.

 

Recent Accounting Pronouncements

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
GOING CONCERN
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 3 - GOING CONCERN

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has no revenue and has an accumulated a deficit as of March 31, 2022. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
COMMON STOCK
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
COMMON STOCK

NOTE 4 – COMMON STOCK

 

On October 10, 2021, the Company amended its Article of Incorporation, increasing its authorized common stock from 100,000,000 to 1,000,000,000 (1 billion), par value $0.0001.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
PREFERRED STOCK
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
PREFERRED STOCK

NOTE 5 – PREFERRED STOCK

 

On October 10, 2021, the Company amended its Article of Incorporation, creating and designating 10,000,000 shares of Series A preferred stock, par value $0.001.

 

Each share of Convertible Series A Preferred Stock is convertible into 1,000 shares of common stock. In addition, the Convertible Series A Preferred Stock has voting privileges of 1,000 votes for each share held.

 

Our sole officer and director holds 100% of the Convertible Series A Preferred Stock.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 6 – RELATED PARTY TRANSACTIONS

 

During the three months ended March 31, 2022, Rhonda Keaveney, CEO, advanced the Company $12,281 to pay for general operating expenses, The advance in non-interest bearing and due on demand.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 7– SUBSEQUENT EVENTS

 

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has determined that it does not have any material subsequent events to disclose in these unaudited financial statements.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The Company’s unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the three month period ending March 31, 2022 and not necessarily indicative of the results to be expected for the full year ending December 31, 2022. These unaudited financial statements should be read in conjunction with the financial statements and related notes for the year ended December 31, 2021.

 

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash and cash equivalents

We consider all highly liquid securities with original maturities of three months or less when acquired to be cash equivalents. There were no cash equivalents as of March 31, 2022 and December 31, 2021.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Cash Equivalents, at Carrying Value $ 0 $ 0
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
GOING CONCERN (Details Narrative)
3 Months Ended
Mar. 31, 2022
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenues $ 0
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
PREFERRED STOCK (Details Narrative) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Class of Stock [Line Items]    
Preferred Stock, Shares Authorized 10,000,000,000 10,000,000,000
Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Series A Preferred Stock [Member]    
Class of Stock [Line Items]    
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Related Party Transaction [Line Items]    
Proceeds from Related Party Debt $ 12,281 $ 0
Rhonda Keaveney [Member]    
Related Party Transaction [Line Items]    
Proceeds from Related Party Debt $ 12,281  
XML 29 nuoncology_i10q-033122_htm.xml IDEA: XBRL DOCUMENT 0001066719 2022-01-01 2022-03-31 0001066719 2022-03-31 0001066719 2021-12-31 0001066719 2021-01-01 2021-03-31 0001066719 NONE:PreferredStockSeriesAMember 2020-12-31 0001066719 us-gaap:CommonStockMember 2020-12-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001066719 us-gaap:RetainedEarningsMember 2020-12-31 0001066719 2020-12-31 0001066719 NONE:PreferredStockSeriesAMember 2021-12-31 0001066719 us-gaap:CommonStockMember 2021-12-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001066719 us-gaap:RetainedEarningsMember 2021-12-31 0001066719 NONE:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001066719 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001066719 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001066719 NONE:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001066719 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001066719 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001066719 NONE:PreferredStockSeriesAMember 2021-03-31 0001066719 us-gaap:CommonStockMember 2021-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001066719 us-gaap:RetainedEarningsMember 2021-03-31 0001066719 2021-03-31 0001066719 NONE:PreferredStockSeriesAMember 2022-03-31 0001066719 us-gaap:CommonStockMember 2022-03-31 0001066719 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001066719 us-gaap:RetainedEarningsMember 2022-03-31 0001066719 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001066719 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001066719 NONE:RhondaKeaveneyMember 2022-01-01 2022-03-31 iso4217:USD shares iso4217:USD shares pure 0001066719 false 2022 Q1 --12-31 10-Q true 2022-03-31 false 000-26113 NUONCOLOGY LABS, INC. FL 65-0019376 7339 E. Williams Drive Unit 26496 Scottsdale AZ 85255 602 793.8058 Yes Yes Non-accelerated Filer true false true 98783664 0 0 0 0 12281 0 12281 0 0.001 0.001 10000000000 10000000000 500000 500000 500000 500000 500 500 0.0001 0.0001 1000000000 1000000000 98783664 98783664 98783664 98783664 9878 9878 10837376 10837376 -10860035 -10847754 -12281 0 0 0 12281 0 12281 0 -12281 0 -12281 0 0 0 -12281 0 -0.00 98783664 98283664 0 0 98283664 9828 10808707 -10818535 0 0 0 0 0 0 0 0 98283664 9828 10808707 -10818535 0 500000 500 98783664 9878 10837376 -10847754 0 0 0 0 -12281 -12281 500000 500 98783664 9878 10837376 -10860035 -12281 -12281 0 -12281 0 0 0 12281 0 12281 0 0 0 0 0 0 0 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqv3luL4krpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - <span id="xdx_82C_z51PrMUxKpwg">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NuOncology Labs, Inc. (the “Company”) was incorporated under the laws of the State of Florida on November 6, 1994 as Choice Book &amp; Video, Inc. The company had no business operations at this time. On April 9, 1998, the Company filed an amendment to its Articles of Incorporation and changed its name to Littman Resources, Inc. with a mergers and acquisitions business model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 1998 the Company merged with NuOncology Labs, Inc. whereby NuOncology Labs, Inc. became the surviving company and on June 26, 1998, filed an amendment to its Articles of Incorporation and changed its name to NuOnclology Labs, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NuOncology Labs, Inc. operated as commercial laboratory and provided predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues and other oncological laboratory testing services and products. NLAB’s operations included development, identification, testing and licensing of cancer treatment compounds.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business operations for NuOncology Labs, Inc. were abandoned by former management and a custodianship action, as described in the subsequent paragraph, was commenced in 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Circuit Court of the Nineth Judicial Circuit in and for Orange County, Florida granted the Application for Appointment of Custodian as a result of the absence of a functioning board of directors and the revocation of the Company’s charter. The order appointed Small Cap Compliance, LLC (the “Custodian”) custodian with the right to appoint officers and directors, negotiate and compromise debt, execute contracts, issue stock, and authorize new classes of stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court awarded custodianship to the Custodian based on the absence of a functioning board of directors, revocation of the company’s charter, and abandonment of the business. At this time, the Custodian appointed Rhonda Keaveney as sole officer and director.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Custodian attempted to contact the Company’s officers and directors through letters, emails, and phone calls, with no success.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Small Cap Compliance, LLC (“SCC”) is a shareholder in the Company and applied to the Court for an Order appointing SCC as the Custodian. This application was for the purpose of reinstating NLAB’s corporate charter to do business and restoring value to the Company for the benefit of the stockholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify"> </p> <p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zO4ccWuuVt2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - <span id="xdx_822_ztvSgkekKl62">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgzpAGO4zjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Basis of Presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the three month period ending March 31, 2022 and not necessarily indicative of the results to be expected for the full year ending December 31, 2022. These unaudited financial statements should be read in conjunction with the financial statements and related notes for the year ended December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--UseOfEstimates_zZxc3P9eRFtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMLIbaGRbL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Cash and cash equivalents</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consider all highly liquid securities with original maturities of three months or less when acquired to be cash equivalents. There were <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220331_zRr6FoV1tSH"><span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zZ4W87JCe9X5">no</span></span> cash equivalents as of March 31, 2022 and December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zYHPE7mt2hY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgzpAGO4zjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Basis of Presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the three month period ending March 31, 2022 and not necessarily indicative of the results to be expected for the full year ending December 31, 2022. These unaudited financial statements should be read in conjunction with the financial statements and related notes for the year ended December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--UseOfEstimates_zZxc3P9eRFtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMLIbaGRbL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Cash and cash equivalents</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consider all highly liquid securities with original maturities of three months or less when acquired to be cash equivalents. There were <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220331_zRr6FoV1tSH"><span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zZ4W87JCe9X5">no</span></span> cash equivalents as of March 31, 2022 and December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> 0 0 <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zYHPE7mt2hY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zqwsPqqoZyV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>NOTE 3 - <span id="xdx_822_zTWEJgkUCNIe">GOING CONCERN</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has <span id="xdx_908_eus-gaap--Revenues_do_c20220101__20220331_zAQj2BuJ0ESg">no</span> revenue and has an accumulated a deficit as of March 31, 2022. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0 <p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zKhwAnMMBBC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 – <span id="xdx_823_zEsjkc55h495">COMMON STOCK</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 10, 2021, the Company amended its Article of Incorporation, increasing its authorized common stock from 100,000,000 to 1,000,000,000 (1 billion), par value $0.0001.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_807_eus-gaap--PreferredStockTextBlock_zF4tQilxJK26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 – <span id="xdx_827_z1tDucqQbSD2">PREFERRED STOCK</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 10, 2021, the Company amended its Article of Incorporation, creating and designating <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0uJ07VNDpZ9"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjSI4JP42NWj">10,000,000</span></span> shares of Series A preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzlAykGOJSn5"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwB6Hzf3YXB3">0.001</span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Convertible Series A Preferred Stock is convertible into 1,000 shares of common stock. In addition, the Convertible Series A Preferred Stock has voting privileges of 1,000 votes for each share held.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our sole officer and director holds 100% of the Convertible Series A Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 10000000 10000000 0.001 0.001 <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zUtiEc0Kd8d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 – <span id="xdx_820_zQy59WikKqh9">RELATED PARTY TRANSACTIONS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2022, Rhonda Keaveney, CEO, advanced the Company $<span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RhondaKeaveneyMember_z0p3e70rRrmg">12,281</span> to pay for general operating expenses, The advance in non-interest bearing and due on demand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 12281 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z91X1HvELxR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7– <span id="xdx_824_zsgLIWnNgMR4">SUBSEQUENT EVENTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has determined that it does not have any material subsequent events to disclose in these unaudited financial statements.</p> EXCEL 30 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 31 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 33 73 1 false 6 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nuoncologylabs.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets (Unaudited) Sheet http://nuoncologylabs.com/role/BalanceSheets Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Unaudited) (Parenthetical) Sheet http://nuoncologylabs.com/role/BalanceSheetsParenthetical Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://nuoncologylabs.com/role/StatementsOfOperations Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Sheet http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows (Unaudited) Sheet http://nuoncologylabs.com/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://nuoncologylabs.com/role/OrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://nuoncologylabs.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - COMMON STOCK Sheet http://nuoncologylabs.com/role/CommonStock COMMON STOCK Notes 10 false false R11.htm 00000011 - Disclosure - PREFERRED STOCK Sheet http://nuoncologylabs.com/role/PreferredStock PREFERRED STOCK Notes 11 false false R12.htm 00000012 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://nuoncologylabs.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 00000013 - Disclosure - SUBSEQUENT EVENTS Sheet http://nuoncologylabs.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 13 false false R14.htm 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies 15 false false R16.htm 00000016 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://nuoncologylabs.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://nuoncologylabs.com/role/GoingConcern 16 false false R17.htm 00000017 - Disclosure - PREFERRED STOCK (Details Narrative) Sheet http://nuoncologylabs.com/role/PreferredStockDetailsNarrative PREFERRED STOCK (Details Narrative) Details http://nuoncologylabs.com/role/PreferredStock 17 false false R18.htm 00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://nuoncologylabs.com/role/RelatedPartyTransactions 18 false false All Reports Book All Reports nuoncology_i10q-033122.htm none-20220331.xsd none-20220331_cal.xml none-20220331_def.xml none-20220331_lab.xml none-20220331_pre.xml nuoncology_ex3101.htm nuoncology_ex3102.htm nuoncology_ex3201.htm nuoncology_ex3202.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 35 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nuoncology_i10q-033122.htm": { "axisCustom": 0, "axisStandard": 3, "contextCount": 33, "dts": { "calculationLink": { "local": [ "none-20220331_cal.xml" ] }, "definitionLink": { "local": [ "none-20220331_def.xml" ] }, "inline": { "local": [ "nuoncology_i10q-033122.htm" ] }, "labelLink": { "local": [ "none-20220331_lab.xml" ] }, "presentationLink": { "local": [ "none-20220331_pre.xml" ] }, "schema": { "local": [ "none-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 142, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 0, "keyStandard": 73, "memberCustom": 2, "memberStandard": 4, "nsprefix": "NONE", "nsuri": "http://nuoncologylabs.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nuoncologylabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - COMMON STOCK", "role": "http://nuoncologylabs.com/role/CommonStock", "shortName": "COMMON STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PREFERRED STOCK", "role": "http://nuoncologylabs.com/role/PreferredStock", "shortName": "PREFERRED STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://nuoncologylabs.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - SUBSEQUENT EVENTS", "role": "http://nuoncologylabs.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - GOING CONCERN (Details Narrative)", "role": "http://nuoncologylabs.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - PREFERRED STOCK (Details Narrative)", "role": "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative", "shortName": "PREFERRED STOCK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-012022-03-31_custom_RhondaKeaveneyMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Balance Sheets (Unaudited)", "role": "http://nuoncologylabs.com/role/BalanceSheets", "shortName": "Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Balance Sheets (Unaudited) (Parenthetical)", "role": "http://nuoncologylabs.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Statements of Operations (Unaudited)", "role": "http://nuoncologylabs.com/role/StatementsOfOperations", "shortName": "Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2020-12-31_custom_PreferredStockSeriesAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "role": "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit", "shortName": "Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "AsOf2020-12-31_custom_PreferredStockSeriesAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Statements of Cash Flows (Unaudited)", "role": "http://nuoncologylabs.com/role/StatementsOfCashFlows", "shortName": "Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS", "role": "http://nuoncologylabs.com/role/OrganizationAndDescriptionOfBusiness", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN", "role": "http://nuoncologylabs.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nuoncology_i10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 6, "tag": { "NONE_PreferredStockSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Series A [Member]" } } }, "localname": "PreferredStockSeriesAMember", "nsuri": "http://nuoncologylabs.com/20220331", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "NONE_RhondaKeaveneyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rhonda Keaveney [Member]" } } }, "localname": "RhondaKeaveneyMember", "nsuri": "http://nuoncologylabs.com/20220331", "presentation": [ "http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r221", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nuoncologylabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r9", "r176" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r41", "r42", "r43", "r135", "r136", "r137", "r154" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r5", "r37", "r78", "r81", "r87", "r93", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r144", "r148", "r157", "r174", "r176", "r192", "r197" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r4", "r176", "r208", "r209" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r28", "r31", "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of year", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r28", "r158" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r4" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r6", "r7", "r8", "r35", "r37", "r55", "r56", "r57", "r59", "r61", "r65", "r66", "r67", "r93", "r95", "r99", "r100", "r101", "r104", "r105", "r109", "r110", "r114", "r118", "r125", "r157", "r226" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r41", "r42", "r154" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r125" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r176" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 98,783,664 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r24", "r46", "r47", "r48", "r49", "r50", "r54", "r55", "r59", "r60", "r61", "r62", "r63", "r155", "r156", "r195", "r201" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r19", "r20", "r21", "r41", "r42", "r43", "r45", "r51", "r53", "r64", "r94", "r125", "r132", "r135", "r136", "r137", "r139", "r140", "r154", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r25" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General & administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r38", "r52", "r53", "r77", "r138", "r141", "r142", "r202" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r15", "r37", "r82", "r93", "r95", "r96", "r97", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r145", "r148", "r149", "r157", "r174", "r175" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r37", "r93", "r157", "r176", "r193", "r199" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r28" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r28" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r28", "r29", "r30" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r17", "r18", "r21", "r23", "r30", "r37", "r44", "r46", "r47", "r48", "r49", "r52", "r53", "r58", "r78", "r80", "r83", "r86", "r88", "r93", "r95", "r96", "r97", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r156", "r157", "r194", "r200" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nuoncologylabs.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfCashFlows", "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r14", "r39", "r170" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Loan payable \u2013 related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://nuoncologylabs.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r78", "r80", "r83", "r86", "r88" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION AND DESCRIPTION OF BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/OrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r7", "r109" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical", "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical", "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r7", "r109" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "PREFERRED STOCK" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/PreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r7", "r176" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series A Preferred stock, $0.001 par value; 10,000,000,000 shares authorized, 500,000 and shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r26" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Cash advance - related party", "verboseLabel": "Proceeds from Related Party Debt" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nuoncologylabs.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r17", "r18", "r21", "r27", "r37", "r44", "r52", "r53", "r78", "r80", "r83", "r86", "r88", "r93", "r95", "r96", "r97", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r143", "r146", "r147", "r150", "r151", "r156", "r157", "r196" ], "calculation": { "http://nuoncologylabs.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Loss before income taxes" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r134", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r134", "r168", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r166", "r167", "r169", "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r132", "r176", "r198", "r206", "r207" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r41", "r42", "r43", "r45", "r51", "r53", "r94", "r135", "r136", "r137", "r139", "r140", "r154", "r203", "r205" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r22", "r37", "r75", "r76", "r79", "r84", "r85", "r89", "r90", "r91", "r93", "r95", "r96", "r97", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r157", "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r6", "r7", "r8", "r35", "r65", "r66", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r114", "r118", "r123", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r6", "r7", "r125" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r34", "r40" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r6", "r7", "r8", "r35", "r37", "r55", "r56", "r57", "r59", "r61", "r65", "r66", "r67", "r93", "r95", "r99", "r100", "r101", "r104", "r105", "r109", "r110", "r114", "r118", "r125", "r157", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r16", "r19", "r20", "r21", "r41", "r42", "r43", "r45", "r51", "r53", "r64", "r94", "r125", "r132", "r135", "r136", "r137", "r139", "r140", "r154", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r41", "r42", "r43", "r64", "r179" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r37", "r92", "r93", "r157", "r176" ], "calculation": { "http://nuoncologylabs.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets", "http://nuoncologylabs.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r36", "r110", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r124", "r132", "r133", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "COMMON STOCK" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r68", "r69", "r70", "r71", "r72", "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r54", "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and diluted weighted average shares" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nuoncologylabs.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r210": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r211": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r212": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r213": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r214": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r215": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r216": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r217": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r218": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r219": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r220": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r221": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r222": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r223": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r224": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r225": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r226": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r227": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r228": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r229": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r230": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" } }, "version": "2.1" } ZIP 36 0001683168-22-003173-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-22-003173-xbrl.zip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